HNHansen Nasif

Hansen Nasif

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hansen Nasif has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    HISTOLOGICAL ANALYSIS OF HEPATOPROTECTIVE EFFECTS OF EUGENIA UNIFLORA L. LEAF ETHANOLIC EXTRACT IN BALB/C MICE

    by Dian Ayu Juwita, Fitri Rachmaini, Hansen Nasif, Elvi Mayasari, Redha Ilahi

    Objective: The plant Eugenia uniflora L. contains various bioactive compounds, including flavonoids, polyphenols, and terpenoids. These compounds can neutralize free radicals and reduce oxidative damage and inflammation in liver tissues, thereby potentially protecting the liver from damage caused by oxidative stress. The purpose of this study is to assess the effect of Eugenia uniflora L. Leaf Ethanolic Extract (EULEE) administration on the histopathological profile in male mice induced by carbon tetrachloride (CCl4). Methods: A total of 45 mice were assigned into 5 treatment groups, with 9 mice in each group. The negative control group was orally treated with Na-CMC suspension. The positive control group was treated orally with a 10% CCl4 solution. The treatment groups were administered a 10% CCl4 solution orally to induce hepatotoxicity, along with EULEE at doses of 200 mg/kg, 400 mg/kg, and 800 mg/kg BW. EULEE was administered for 7, 14, and 21 d. On days 8, 15, and 22, three mice from each treatment group were euthanized, and their liver organs were collected for histology analysis followed the Manja Roenigk Histopathology Scoring System. Statistical analysis was performed using two-way ANOVA. Results: The administration of EULEE 200, EULEE 400, EULEE 800 resulted in a reduction of liver histology scores compared to the positive control group, indicating a decrease in the level of liver tissue damage. The average histology scores for the three dosage groups were 39.556±0.0555, 47.600±0.555, and 45.333±0.555. Conclusion: The administration of EULEE results in an improvement in the liver's histological features in mice.

  • Open Access

    Observing the uncertainty of the Amlodipine-Candesartan Incremental Cost-Effectiveness ratio using Deterministic Sensitivity Analysis (DSA)

    by Najmiatul Fitria, Yolanda Zazna Syaputri, Lailaturrahmi Lailaturrahmi, Hansen Nasif

    Background: Hypertension treatment is carried out for a long time and can cause quite large costs. This study delves into the economic evaluation of Amlodipine-Candesartan combination therapy, a prominent treatment for hypertension. While the clinical benefits of this regimen are well-documented, its cost-effectiveness remains a critical consideration for healthcare systems. Employing Deterministic Sensitivity Analysis (DSA). This study aimed to discern the uncertainty surrounding the Incremental Cost-Effectiveness Ratio (ICER) associated with Amlodipine-Candesartan through comprehensive examination, next to refine economic assessments and offer insights for healthcare policymakers and practitioners. Method: This retrospective descriptive study at Andalas University Hospital in 2021 analyzed hypertension outpatient data. Of 284 patients, 73 were included. Among them, 28.77% received Amlodipine monotherapy, while 71.23% received Amlodipine-Candesartan combination therapy. Results: The ICER for systolic blood pressure was Rp. 74,738.10 per mmHg decrease, and for diastolic blood pressure, it was Rp. 205,918.24 per mmHg decrease. Both of them are in the northeast quadrant. Next, DSA will be carried out by creating a tornado diagram by providing a change range of 20% (min-max) for the input variables in ICER. Conclusion: The use of amlodipine-candesartan requires a higher cost, but the resulting effect is also better. Our findings contribute to the broader discourse on combination therapies and inform resource allocation strategies for hypertension management. This research attempts to enhance the precision of economic evaluations, ultimately facilitating more informed and efficient healthcare decision-making processes. Keywords: Amlodipine, Candesartan, Cost-effectiveness, ICER, DSA.

  • Open Access

    Amlodipine-Candesartan Combination: A Cost-Effective Strategy for Successful Therapy of Hypertension

    by Najmiatul Fitria, Yolanda Zazna Syaputri, Mardatillah Mardatillah, Muhammad Akram, Hansen Nasif

    Introduction: The combination of amlodipine and candesartan can have a better effect, although the cost-effectiveness analysis was not yet determined. This research aimed to establish the Incremental Cost-Effectiveness Ratio (ICER) value among outpatients with hypertension who used amlodipine-candesartan. Method: This research is a descriptive study that retrospectively gathered data from medical records. It focused on information for hypertensive patients at Universitas Andalas Hospital in 2021. This study compared the standard treatment involving amlodipine-candesartan and sole amlodipine, next to calculate the ICER using cost-effectiveness analysis. Results: Out of the total population of 284, as many as 73 patients were involved in this study. Among these, 21 patients (28.77%) were treated with amlodipine alone, while 52 (71.23%) received an amlodipine-candesartan combination. The Incremental Cost-Effectiveness Ratio (ICER) for reducing systolic blood pressure was IDR 74,738.10 per one mmHg decrease in the northeast quadrant of the cost-effectiveness chart. The ICER for lowering diastolic blood pressure was IDR 205,918.24 per one mmHg decrease in the northeast quadrant on the cost-effectiveness chart. Conclusion: The cost of the amlodipine-candesartan combination yields superior effects; however, warranting a probabilistic sensitivity analysis to determine its ICER robustness is essential for its effective implementation


  • Open Access

    COST-EFFECTIVENESS OF METFORMIN-GLIMEPIRIDE COMBINATION COMPARED TO SINGLE METFORMIN USE IN DECREASING 2 H POST PRANDIAL BLOOD GLUCOSE

    by Najmiatul Fitria, Mila Andela, Resna Rerita, Hansen Nasif

    Objective: Complications related to diabetes could reduce the quality of life. In Indonesia, the costs incurred for diabetes mellitus annually will increase as complications of the disease increase. This study explored the cost-effectiveness therapy of metformin-glimepiride combination on post-prandial blood glucose. Methods: Glimepiride is added to the first category for diabetes mellitus receiving metformin to improve blood sugar levels and reduce costs. An observational study was conducted retrospectively to analyze post-prandial blood sugar levels with the total direct medical costs at Universitas Andalas Hospital. The study involved 114 medical records of patients referred during 2021. The combination of Metformin HCL and Glimepiride was compared to Metformin alone in measuring cost and effect parameters. The categorical dependent-independent groups were statistically analyzed using Chi-square, while the cost and effect parameters were calculated to get the Incremental Cost-Effectiveness Ratio (ICER) value. Results: There were no significant differences between groups on sociodemographic characteristics (p<0.05). An incremental cost value of IDR 43,291 was obtained for reducing post-prandial blood sugar by 21.92 mg/dl. Conclusion: Increasing cost and effect parameters require further analysis to determine the trade-off point.